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Mannose-capped lipoarabinomannans (Man-LAMs) are mem-
bers of the repertoire ofMycobacterium tuberculosismodulins that
the bacillus uses to subvert the host innate immune response. Inter-
leukin-12 (IL-12) production is critical for mounting an effective
immune response by the host against M. tuberculosis. We demon-
strate that Man-LAM inhibits IL-12 p40 production mediated by
subsequent challenge with lipopolysaccharide (LPS). Man-LAM
inhibits LPS-induced IL-12 p40 expression in an IL-10-independ-
ent manner. It attenuates LPS-induced NF-B-driven luciferase
gene expression, suggesting that its effects are likely directly related
to inhibition of NF-B. This is probably because of dampening of
the Toll-like receptor signaling. Man-LAM inhibits IL-1 receptor-
associated kinase (IRAK)-TRAF6 interaction as well as IB- phos-
phorylation. It directly attenuates nuclear translocation and DNA
binding of c-Rel andp50.Man-LAMexerts these effects by inducing
the expression of Irak-M, a negative regulator of TLR signaling.
Knockdown of Irak-M expression by RNA interference reinstates
LPS-induced IL-12 production in Man-LAM-pretreated cells. The
fact that Irak-M expression could be elicited by yeast mannan
suggested that ligation of the mannose receptor by the mannoo-
ligosaccharide caps of LAMwas the probable trigger for IRAK-M
induction.
Mycobacterum tuberculosis is the causative agent of tuberculosis,
which leads to an estimated 2 to 3 million deaths worldwide each year.
The organism evades the immune response of the host bymanipulating
host cell signaling pathways (1). One of the important mechanisms is
the suppression of interleukin-12 (IL-12)3 production. IL-12 is a het-
erodimeric cytokine composed of two disulfide-linked subunits of 35
(p35) and 40 (p40) kDa encoded by two separate genes (2–4). It is
produced by macrophages and dendritic cells in response to infection
with bacteria or exposure to bacterial constituents such as lipopolysac-
charide (LPS) (2, 4). It is required for cell-mediated immunity and host
defense against intracellular microbes (5). IL-12 is critical for the gen-
eration of Th1 responses againstM. tuberculosis infection. In support of
this view are the observations that individuals with mutations affecting
the genes of IL-12 (6) or its receptor (7, 8) have increased susceptibility
to mycobacterial infections. IL-12-deficient mice are susceptible to
Mycobacterium bovis bacillus Calmette-Guerin infection (9). This
underscores the need to understand how M. tuberculosis dampens
IL-12 production. Intracellular bacteria and bacterial products regulate
IL-12 production at the transcriptional level (10). The best studied tran-
scriptional regulation of the IL-12 p40 promoter is mediated by binding
of Rel family members effecting induction of a Th1 immune response
(11–13). We therefore considered the possibility of M. tuberculosis
modulins dampening this pathway.
Lipoarabinomannan (LAM) is a cell wall lipoglycan. LAMs have been
considered modulins because of their capacity to manipulate the host
immune system. To date, three families of LAMshave been described (14).
A glycosylphosphatidylinositol anchor, a D-mannan core, and a large ter-
minal D-arabinan represents the core structure. The arabinan domain is
capped by either mannosyl (15–18) or phosphoinositol residues (19, 20).
Themannose-cappedLAMs (Man-LAMs) are found inpathogenic species
including M. tuberculosis (14). Phosphoinositol-capped LAMs have been
isolated from non-pathogenic species such asMycobacterium smegmatis.
Phosphoinositol-capped LAMs activate macrophages in a Toll-like recep-
tor (TLR) 2-dependent manner by activating NF-B-dependent pathways
(21).MycobacterialMan-LAMs on the other hand, modulate the immune
response by dampening IL-12 production in macrophages and dendritic
cells (22, 23) and attenuating apoptotic signaling (24, 25). The emerging
consensus is thatMan-LAM contributes to the capacity ofM. tuberculosis
to survive inside macrophages by mediating immunosuppressive effects.
Recent studies have demonstrated that lipomannans induce IL-12 produc-
tion (26) in a TLR-dependent manner and may also inhibit IL-12 produc-
tion in a TLR-independent manner (27), suggesting that the ratio of lipo-
mannans to Man-LAM may govern the capacity of the organism to
circumvent IL-12 production.The anti-inflammatory effects ofMan-LAM
have been attributed to their binding to the mannose receptor (23) or to
DC-specific intercellular adhesion molecule 3 grabbing nonintegrin
(28, 29).
Stimulation through TLRs by pathogen-associated molecular pat-
terns, such as LPS triggers production of various cytokines, including
IL-12, which is crucial for induction of Th1 responses (10, 31). The
resultant inflammatory response is essential for the eradication of infec-
tious microorganisms. However, excessive and prolonged activation of
innate immunity is harmful to the host. To prevent such an undesirable
outcome, the innate immune system has dampening mechanisms to
prevent continued inflammatory signaling in response to repeated chal-
lenge by pathogenic stimuli. Dampening of the proinflammatory
response may occur by multiple processes, which often lead to limited
activation of NF-B. Four different IL-1 receptor-associated kinases
(IRAKs) have been identified. IRAK-M is devoid of kinase activity and is
restricted to monocytes/macrophages. It negatively regulates TLR sig-
naling (32, 33). Suppressor of cytokine signaling-1 is another inducible
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negative regulator of TLR signaling, although its induction occurs only
through TLR4 (34, 35). Additional safety systems to control the magni-
tude of NF-B activation involve phosphatidylinositol 3-kinase, which
negatively regulates TLR signaling and likely functions at the early
stages of encounter to pathogens (36, 37).
In this study, we have demonstrated that Man-LAM fromM. tuber-
culosis suppresses LPS-induced IL-12 p40 protein production, mRNA
expression, and promoter activity in murine RAW264.7 macrophages
by inhibiting LPS-induced IRAK-TRAF6 interaction, IB- phospho-
rylation, and nuclear translocation of c-Rel and p50. Silencing of Irak-M
by RNA interference supports our view that Man-LAM dampens IL-12
p40 production through an IRAK-M-mediated pathway. Whereas the
inhibitory effect of Man-LAM on IL-12 production is widely acknowl-
edged, the mechanism has remained obscure. Our studies provide
mechanistic insight into how a mycobacterial modulin functions to
dampen TLR signaling.
EXPERIMENTAL PROCEDURES
Reagents—Anti-IRAK-M, anti--actin, anti-FLAG antibody, anti-
FLAG-agarose, cycloheximide, and Escherichia coli LPS were from
Sigma. Anti-TRAF6 and anti-IRAK1 antibody were from Santa Cruz
Biotechnology, and anti-phospho-IB- antibody was fromCell Signal-
ing Technology, Beverley, MA.
Cell Culture—The murine macrophage cell line RAW264.7 was
obtained from the National Center for Cell Science, Pune, India, and
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM glutamine and antibiotics.
Mycobacterial Lipids—Endotoxin free Man-LAM from M. tubercu-
losisH37Rv, and phosphoinositol-capped LAMwere kindly provided by
Dr. John Belisle, Colorado State University, Fort Collins, CO. Lipids
were dissolved at a concentration of 1 mg/ml in pyrogen-free water and
diluted with medium before each experiment.
Plasmid Constructs—4 NF-B-luc containing four NF-B sites in
tandem fused to the luciferase reporter gene, was a gift fromDr.A. Brent
Carter of the University of Iowa. Murine IL-12 p40 promoter (350 to
55) was a gift from Prof. Stephen Smale, Howard Hughes Medical
Institute, University of California, Los Angeles, CA.
RNA Isolation and Reverse Transcription (RT)-PCR—Total RNA was
prepared from cells using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s protocol. 100 ng of RNAwas reverse transcribed using the
TitaniumOne-Step RT-PCRKit (Clontech). 363 bp of Irak-MmRNA and
417 bp of IL-12 p40mRNAwere amplified by using the primer pairs 5-T-
CTTCAGGTGTCCTTCTCCACTGT-3(sense) and 5-CCTCTTCTC-
CATTGGCTTGCTCCCAT-3(antisense) for Irak-M, and 5-GGAGAC-
CCTGCCCATTGAACT-3 (sense) and 5-CAACGTTGCATCCTAG-
GATCG-3 (antisense) for IL-12 p40. Glyceraldehyde 3-phosphate dehy-
drogenase (gapdh) was amplified using the primers 5-CCATCAATGAC-
CCCTTCATTGACC-3 (sense) and 5-GAAGGCCATGCCAGTGAG-
CTTCC-3 (antisense) to generate a 604-bp product.
Western Blotting—Proteins were separated by SDS-PAGE and trans-
ferred electrophoretically to polyvinylidene difluoride membranes. The
blotswere blockedwith 5%nonfat drymilk inTris-buffered saline (TBS)
for 1 h at room temperature and subsequently incubated overnight at
4 °C with primary antibodies in TBS-Tween 20 (1%, v/v) (TBST) with
5% (w/v) bovine serum albumin. Following three washes of 5 min each
with TBST, the blots were incubated with horseradish peroxidase-con-
jugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Inc.) at a dilu-
tion of 1:1,000 in blocking buffer for 1 h at room temperature. After 3
washes with TBST, the blots were developed by chemiluminescence
using the phototope-horseradish peroxidase Western Detection Kit
(Cell Signaling Technology) and exposed to x-ray film (Kodak X-AR5).
LuciferaseReporterAssays—RAW264.7cellswere transfectedwith lucif-
erase reporterplasmidconstructsusingLipofectamine reagent (Invitrogen)
according to the manufacturer’s instructions. Transfected cells after treat-
mentwere lysed in25mMTris-HCl,pH7.8, containing2mMdithiothreitol,
1%TritonX-100, 4mMEGTA, 10% glycerol, 20g/ml aprotinin, 10g/ml
pepstatin, and 10 g/ml leupeptin, centrifuged, and the supernatant
assayed for luciferase activity. Resultswere normalized for transfection effi-
ciencies by assay of -galactosidase activity.
Enzyme-linked Immunoassay for IL-12 p40—6  104 RAW264.7
cells (plated in each well of a 96-well plate) were either left untreated or
treatedwithMan-LAM for 16 h.Man-LAMwas then removed and cells
were incubated in fresh medium without or with LPS for a further 24 h.
The conditioned medium was removed and assayed for IL-12 p40 by
enzyme-linked immunosorbent assay using the murine IL-12 p40 assay
kit (BD Biosciences).
Co-immunoprecipitation of TRAF6 and IRAK1—RAW264.7 cells
transfected with FLAG-TRAF6 were washed with cold phosphate-
buffered saline and lysed for 15 min on ice in 0.5 ml of lysis buffer (50
mMTris-HCl, pH 8, containing 280mMNaCl, 0.5%Nonidet P-40, 0.2
mM EDTA, 2 mM EGTA, 10% glycerol, 1 mM dithiothreitol, 1 mM
Pefabloc, and 1 g/ml aprotinin). Cell lysates were clarified by cen-
trifugation for 10 min at 15,000  g in a Microfuge and incubated
with 2 g of anti-FLAG-agarose overnight at 4 °C with gentle rocking.
Immunoprecipitateswerewashed, denatured in SDSgel denaturing buffer,
proteins were separated electrophoretically, transferred on to polyvi-
nylidene difluoride membranes, and immunoblotted with anti-IRAK1
antibody.
Western Blotting for Phospho-IB-—RAW264.7 cells after treat-
ment were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mMNaCl,
1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 5 mM EGTA, 50
mMNaF, 12mM sodium-glycerophosphate, 1mMdithiothreitol, 1mM
Na3VO4, 1 mM Pefabloc, and 1 g/ml aprotinin). Lysates after clarifica-
tion were separated by 10% SDS-PAGE, electrotransferred on to poly-
vinylidene difluoride, and immunoblottedwith phospho-IB--specific
antibody. When required, blots were reprobed with anti--actin anti-
body to confirm equal loading in all lanes.
Generation and Transfection of Small Interfering RNA Constructs for
Irak-M—A vector-based system was used to knock down Irak-M by
RNA interference using the pSuppressor Neo vector (Imgenex Corpo-
ration). The target sequences for murine Irak-M were 5-TGTCCCA-
AGTATTCCAGTA-3 (S1) and 5-GTCCTACTGTGATCAGTTT-3
(S2). Cloning was carried out between the SalI and XbaI sites of the
vector. All constructs were verified by sequencing. RNA interference
expression vectors or control vector (containing a scrambled sequence
from Imgenex that did not show significant sequence homology to rat,
mouse or human gene sequences)were transfected intoRAW264.7 cells
using Lipofectamine (Invitrogen).
NF-B Assay—Nuclear extracts from cells were prepared using the
TransFactor extraction kit (Clontech). After centrifugation for 5 min at
20,000 g at 4 °C, supernatants were assayed for the presence of c-Rel
and p50. An equal amount of nuclear lysate was added to incubation
wells precoated with the DNA-binding consensus sequence. The pres-
ence of translocated NF-B c-Rel or p50 subunit was then assessed by
using the Mercury TransFactor kit (Clontech) according to the manu-
facturer’s instructions. Plates were read at 655 nm.
Statistical Analysis—Statistical significance between groups was
evaluated by Student’s t test. Differences were considered significant at
the level of p 0.05.
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RESULTS
Man-LAM Inhibits LPS-induced IL-12 p40 mRNA Expression and Pro-
teinRelease inRAW264.7Cells—TodeterminewhetherMan-LAMaffects
IL-12 p40 expression and release in RAW264.7murinemacrophages, cells
were pretreatedwithMan-LAM, followedby challengewith LPS (1g/ml)
for 4 (for mRNA expression) or 24 h (for IL-12 release). Pretreatment of
cellswithMan-LAMinhibitedLPS-induced IL-12p40mRNAinduction in
a dose-dependent manner (Fig. 1A) as assessed by RT-PCR. Pretreatment
FIGURE1.Man-LAMmodulatesLPS-induced IL-12p40productionand inhibitsLPS-induced IL-12promoter-driven luciferase reporterexpressionandnuclear translocation
of c-Rel/p50 family members in RAW264.7 macrophages. Panel A, IL-12 p40 mRNA was analyzed by RT-PCR using RNA isolated from cells incubated without (lane 1) or with
Man-LAMat concentrationsof 5 (lane3) and10g/ml (lanes 4and5) for 16h followedby incubationwithout (lane5) orwithLPS (1g/ml) (lanes 3and4). Glyceraldehyde-3-phosphate
dehydrogenase (gapdh) was used as a control. Panel B, cells were left untreated (C) or treated either with Man-LAM or with LPS at the indicated concentrations. IL-10 mRNA was
analyzed by RT-PCR as described. Panel C, RAW264.7 cells were incubated without or with the indicated concentrations of Man-LAM for 16 h followed by treatment without or with
LPS(1 g/ml). Panel D, cells were preincubated without or with cycloheximide (CHX, 10 g/ml) for 15 min followed by incubation without or with Man-LAM (10 g/ml) alone, or
Man-LAM in combinationwithneutralizing IL-10monoclonal antibody (10g/ml) or control IgG for 16hprior to treatmentwith LPSasdescribedunderpanel B. Cell-free supernatants
were collectedand IL-12p40wasmeasuredbyenzyme-linked immunosorbent assay forpanels CandD. Results underpanelsAandBare representativeof the results obtained in three
independent experiments. Results in panels C and D represent the mean  S.D. of three independent experiments. *, p  0.001; **, p  0.5 versus cells treated with LPS alone.
RAW264.7 cells were transfected with the IL-12 promoter (350 to55)-luciferase reporter (panel E) or 4 B-luciferase (panel F) and -galactosidase constructs. Transfected cells
were left untreated, or treatedwithMan-LAM (10g/ml) for 16h. Cellswere subsequently incubatedwithout orwith LPS (1g/ml) for 16h. Following incubations, luciferase reporter
activities in the cell extracts were measured using luciferin as substrate. In each case, the level of induction of luciferase activity is expressed relative to that of untreated cells. The
activities shown represent data that have been normalized with -galactosidase activity. Results represent the mean S.D. of three independent experiments. *, p 0.001, versus
cells treated with LPS alone. Panel G, cells were left untreated or pretreated with Man-LAM, followed by incubation without or with LPS as described above. Nuclear extracts were
prepared, and p50, c-Rel, or c-Fos translocation was measured according to the manufacturer’s protocol. Results represent mean S.D. of three independent experiments. *, p
0.001; **, p 0.5 versus cells treated with LPS alone.
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of cells with Man-LAM also resulted in a dose-dependent inhibition of
IL-12 p40 release (Fig. 1C), in harmony with previous reports (23). Phos-
phoinositol-capped LAMdid not inhibit either LPS-induced IL-12 protein
release or IL-12 p40 mRNA expression (data not shown). The effect of
Man-LAM on LPS-induced IL-12 release could be abrogated when cells
were pretreated with the protein synthesis inhibitor cycloheximide fol-
lowed by treatment with Man-LAM (Fig. 1D), suggesting that the inhibi-
tory effect of Man-LAMwas dependent on de novo protein synthesis.
Inhibition of LPS-induced IL-12 p40 Induction by Man-LAM Is Inde-
pendent of IL-10—IL-10 is a potent inhibitor of IL-12 gene expression
and protein production (38). To assess whether the inhibitory effect of
Man-LAM on IL-12 p40 production was because of IL-10-dependent
effects, induction of IL-10 mRNA was analyzed. As a positive control,
IL-10 mRNA expression was observed by RT-PCR in RAW264.7 cells
treated with LPS at concentrations of 5 and 10 g/ml (Fig. 1B), in
accordance with the observations of Brightbill et al. (39). However,
Man-LAM (at concentrations up to 10 g/ml) did not induce IL-10
release in RAW264.7 macrophages in agreement with previous reports
(40). In addition, when RAW264.7 macrophages were treated with
Man-LAM in the presence of neutralizing antibody to IL-10, no effect
was observed on the ability of Man-LAM to suppress LPS-induced
IL-10 production (Fig. 1D). We therefore concluded that down-regula-
tion of LPS-induced IL-12 production by Man-LAM is not dependent
on IL-10-mediated effects.
Man-LAM Inhibits LPS-induced IL-12 p40 Promoter Activity—To
analyze the molecular mechanisms of inhibition of IL-12 p40 gene
expression by Man-LAM, the ability of Man-LAM to modulate LPS-
induced IL-12 p40 promoter-driven luciferase gene expression was
determined. Cells were transfected with an IL-12 p40 promoter (350
to 55)-luciferase construct, pretreated with Man-LAM for 16 h and
then stimulated with LPS for 16 h. Man-LAM inhibited LPS-induced
IL-12 promoter activity by 50% (Fig. 1E), suggesting that Man-LAM
attenuated LPS-induced activation of the IL-12 promoter.
LPS-induced cytokine gene expression in macrophages is the
result of signaling through TLR4, a member of the family of pattern
recognition receptors. NF-B is a target of TLR signaling (41–43).
This signaling pathway commonly involves MyD88-dependent
IRAK activation (44, 45), its phosphorylation and association with
TNF receptor-associated factor-6 (TRAF6) leading to IB kinase
activation, IB- phosphorylation and degradation, culminating in
release of NF-B facilitating its translocation to the nucleus. NF-B
binding to the IL-12 promoter synergizes with the binding of other
transcription factors to activate the IL-12 promoter (12). We asked
the question whether Man-LAM inhibits NF-B activation. Cells
were transfected with a multimerized NF-B luciferase reporter
plasmid to study the effect of Man-LAM on LPS-induced NF-B-
driven luciferase gene expression. Pretreatment of cells with Man-
LAM prior to stimulation with LPS led to a consistent reduction in
luciferase reporter activity (Fig. 1F), lending support to the view that
the inhibitory effect of Man-LAM is likely exerted at the level of
NF-B-dependent gene expression.
Inhibition of DNABinding of Rel Family Proteins byMan-LAM—LPS
stimulates the translocation of p50/c-Rel heterodimers to the nucleus in
RAW264.7macrophages (47) with c-Rel being essential for activation of
the p40 gene (48). Considering that Man-LAM inhibits LPS-induced
IB- phosphorylation, we asked the question whether Man-LAM
inhibits nuclear translocation and consequent DNA binding of the Rel
family of proteins. Nuclear extracts from cells left untreated or pre-
treated with Man-LAM followed by challenge with LPS were tested for
binding to consensus NF-B sequences. Binding of c-Rel and p50 was
expectedly inhibited in cells pretreated with Man-LAM (Fig. 1G). On
the other hand, Man-LAM did not influence LPS-induced c-Fos trans-
location into the nucleus, suggesting that the effect of Man-LAM was
specific for Rel family members.
Man-LAM Inhibits IB- Phosphorylation in LPS-treated RAW264.7
Cells—In view of the fact that TLR signaling leads to the phosphoryla-
tion of IB-, prior to its degradation and the release of IB--seques-
tered NF-B, we assessed the effect of Man-LAM on LPS-induced
IB- phosphorylation. LPS-induced IB- phosphorylationwas found
to be significantly reduced in cells pretreated with Man-LAM (Fig. 2A),
supporting the view that Man-LAM inhibits TLR signaling resulting in
decreased IB- phosphorylation.
Man-LAM Attenuates the Interaction of IRAK with TRAF6—In the
classical pathway of TLR4 signal transduction, the adaptor molecule
MyD88 is recruited to the cytoplasmic tail of TLR4 following activation
with LPS, followed by recruitment of IRAK. IRAK is then phosphoryl-
ated, and leaves the TLR4-MyD88 complex prior to its interaction with
TRAF6, a downstream transducer that finally leads to IB kinase acti-
vation, IB- phosphorylation, its degradation, and release of NF-B
facilitating its translocation to the nucleus. Considering thatMan-LAM
was capable of inhibiting LPS-induced IB- phosphorylation, we
explored the possibility of Man-LAM inhibiting an upstream event
along the cascade. The interaction of IRAK and TRAF6 was tested after
transfecting cells with FLAG-TRAF6. Transfected RAW264.7 cells
were pretreated with Man-LAM prior to challenge with LPS. After
treatment, proteins were immunoprecipitated from whole cell lysates
with anti-FLAG antibody-bound agarose, and immunoblotted with
IRAKantibody. The physical interaction between IRAKandTRAF6was
abrogated in cells pretreated with Man-LAM (Fig. 2B). No band corre-
sponding to IRAK was obtained when immunoprecipitation was per-
formed with Protein A/G-agarose only. This result argued in favor of a
FIGURE2.Man-LAMattenuates LPS-induced IB-phosphorylationand IRAK-TRAF6 interaction inRAW264.7macrophages.A, RAW264.7 cellswerepreincubatedwithout or
with Man-LAM (10 g/ml) for 16 h followed by treatment without or with LPS (1 g/ml) for the indicated time. The cell lysates were probed with anti-phospho-IB- antibody and
then reprobedwith anti-actin antibody to ensure equal loading of gels. B, RAW264.7 cellswere transfectedwith FLAG-tagged TRAF6 andpreincubatedwith orwithoutMan-LAM (10
g/ml) followedby treatmentwith LPS (1g/ml). Cell lysateswere incubatedwith anti-FLAG-agarose (lanes 1–4) or ProteinA/G-agarose alone (lane 5). Agarose-boundproteinswere
separated by SDS-PAGE and immunoblottedwith anti-IRAK1 antibody (lanes 1–6). Blots were probedwith anti-FLAG (lanes 1–4) to show loading of gels. Lane 6 represents a positive
control with immunoprecipitated IRAK1 only. Results are representative of those obtained in three independent experiments.
LAM-mediated IRAK-M Induction Inhibits IL-12 p40 Induction
DECEMBER 30, 2005•VOLUME 280•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 42797
 by guest on January 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
specific interaction between IRAK and TRAF6 that could be inhibited
by Man-LAM.
Man-LAM Induces Irak-M Expression—Because Man-LAM inhib-
ited the IRAK-TRAF6 interaction, we searched for possible involve-
ment of negativemodulators of this interaction inMan-LAM-mediated
inhibition of NF-B activation. IRAK-M is a negative modulator of
TLR4 signaling that is restricted to monocytes and macrophages (32,
33). Previous studies have reported that IRAK-M can compete with
IRAK1 for binding to TRAF6 (33). Because pre-exposure to Man-LAM
dampens the release of IL-12 by secondary stimulation with an inducer
such as LPS, we reasoned thatMan-LAM likely acts in a manner akin to
the mechanism of induction of endotoxin tolerance where IRAK-M
plays a central role (32). Therewas a dose-dependent increase in Irak-M
mRNA levels in cells treated with Man-LAM for 3 h (Fig. 3A). In addi-
tion, there was a time-dependent increase of IRAK-M protein in cells
treated with Man-LAM (Fig. 3B).
Specific Down-regulation of Irak-M Abolishes the Inhibitory Effect of
Man-LAM on LPS-induced IL-12 Production—We tested whether
experimental modulation of Irak-M expression would alterMan-LAM-
mediated suppression of LPS-induced IL-12 production. RNA interfer-
ence using a vector-based system was employed for knocking down
IRAK-M expression. RAW264.7 cells were transfected with each of the
two plasmids containing the Irak-M silencing sequences (S1 and S2)
individually or in combination, orwith a scrambled sequence bearing no
homology to any human gene. Irak-M gene expression (Fig. 3C) and
LPS-induced IL-12 promoter-driven luciferase expression (Fig. 3F)
were down-regulated in cells transfected with plasmids containing the
S1 and S2 inserts, but not with the plasmid containing the scrambled
insert. Down-regulation was more pronounced in cells cotransfected
with both S1 and S2 bearing inserts, compared with either expression
vector used alone. Both the expression vectors were therefore cotrans-
fected in subsequent experiments. The inhibitory effects of Man-LAM
FIGURE3.Man-LAM-induced Irak-Mexpression inRAW264.7macrophagesandeffectsof silencing its expressionbyRNA interference.Panel A, RAW264.7 cellswereeither left
untreated or treated with Man-LAM at concentrations of 2.5 (lane 2), 5 (lane 3), and 10 (lane 4)g/ml. Irak-MmRNAwas quantitated by RT-PCR. Panel B, RAW264.7 cells were treated
withMan-LAM (5g/ml) for the indicated timeperiods. Total cell lysateswereblottedwith an antibody specific for IRAK-M. Toensure equal loading, cell lysateswere alsoprobedwith
anti--actin antibody. Results are representative of those obtained in three independent experiments. Bars represent mean  S.D. of three independent experiments. Panel C,
RAW264.7 cells were either left untreated or transfected with constructs carrying inserts of small interfering RNAs directed against different (S1, S2) sequences of Irak-M, alone or in
combination; or a construct carrying a scrambled control sequence. Cells were then incubated without or with Man-LAM (5 g/ml) for 16 h prior to isolation of RNA and analysis of
Irak-MexpressionbyRT-PCR.PanelsD and E, RAW264.7 cellswere transfectedwith constructs carrying inserts of small interferingRNA (siRNA) (S1 S2) for Irak-Mor control scrambled
sequence. Cells were then pretreated without or withMan-LAM (5g/ml) followed by treatment with LPS (1g/ml). IL-12 p40mRNAwas analyzed by RT-PCR (panel D) as described
under panel A and IL-12 p40 releasewasmeasured by enzyme-linked immunosorbent assay (panel E). Panels F andG, RAW264.7 cells were transfectedwith the IL-12promoter (350
to55)-luciferase reporter (panel F) or 4 B-luciferase (panel G) and -galactosidase constructs; along with constructs harboring inserts of small interfering RNA (siRNA) of Irak-M
(S1 and S2) or scrambled sequence as indicated. Transfected cells were left untreated, or treated with Man-LAM. Cells were subsequently incubated without or with LPS. Following
incubation, luciferase reporter activities in the cell extractsweremeasuredusing luciferin as substrate. In each case, the level of inductionof luciferase activitywas comparedwith that
of untreated cells. The activities shown represent data that have been normalizedwith -galactosidase activity. Results representmean S.D. of three independent experiments. *,
p 0.001; **, p 0.5 versus cells treated with LPS alone.
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on LPS-induced IL-12 gene expression (Fig. 3D) and IL-12 release (Fig.
3E) were abrogated in cells cotransfected with both expression vectors.
RNA interference also showed that the effect ofMan-LAM in inhibiting
NF-B-driven luciferase gene expression was abrogated by silencing
Irak-M, suggesting that LAM-induced IRAK-M dampens NF-B acti-
vation (Fig. 3G).
Effect of Mannan on IRAK-M Production in RAW264.7 Cells—Man-
LAM targets the mannose receptor (MR) in macrophages (48, 49). The
MR recognizes glycosylated molecules with terminal mannose, fucose,
and N-acetylglucosamine moieties (50). Its role in pathogen-triggered
signaling is beginning to be appreciated (51). Nigou et al. (23) have
reported that Saccharomyces cerevisiae mannan could inhibit LPS-in-
duced IL-12 release from dendritic cells. To test whether ligation of the
MR is involved in IRAK-M production, cells were treated with Saccha-
romyces cerevisiaemannan, a known ligand of theMR.Mannan elicited
a dose-dependent increase in Irak-M gene (Fig. 4A) and protein (Fig. 4B)
expression. Polymyxin B did not have any bearing on the effect of man-
nan (Fig. 4A), confirming that LPS contamination was not responsible
for the observed effect ofmannan. This result suggested that interaction
of the MR with mannooligosaccharide caps of Man-LAM was likely
partly responsible for Man-LAM-mediated Irak-M expression. The
involvement of receptors other than the MR, as well as moieties of
Man-LAM other than the mannooligosaccharide caps, in this process,
remains to be explored.
DISCUSSION
Dampening of the Th1 response favors survival of pathogenic myco-
bacteria within macrophages. It is therefore not surprising that M.
tuberculosis has evolved strategies to dampen release of cytokines such
as IL-12, which are crucial for a Th1 response. A variety of effectors
likely acts in a spatially and temporally controlledmanner tomanipulate
host signaling pathways to the benefit of the bacterium. One of the
better studied of these mycobacterial modulins is Man-LAM of M.
tuberculosis. Man-LAMs have clearly emerged as anti-inflammatory
molecules inhibiting the production of TNF- and IL-12 by human
macrophages/dendritic cells (52). However, little is known about the
underlying mechanisms. In this paper we provide mechanistic insight
into Man-LAM-mediated suppression of IL-12 production in
RAW264.7 macrophages.
Biologically active IL-12 is a heterodimer composed of two subunits,
p40 and p35. The p35 gene is constitutively expressed, whereas the p40
gene is expressed only in cells that produce bioactive IL-12 (4). We
therefore focused our attention on understanding the regulation of
IL-12 p40 production. IL-12 p40 expression is inducible inmacrophages
and dendritic cells (53, 54) and is regulated primarily at the transcription
level in monocytic cells (55). Using LPS as an agonist of IL-12 produc-
tion in RAW264.7 cells, we observed that Man-LAM inhibited both the
production of IL-12 p40 protein and expression of the IL-12 p40mRNA.
Multiple control elements have been demonstrated to regulate IL-12
p40 transcription in response to microbial products including LPS (11,
12, 56, 57). Man-LAM did not induce IL-10 gene expression. Using
neutralizing antibodies against IL-10 we have demonstrated that the
inhibitory effect of Man-LAM is not dependent on IL-10. Pretreatment
with Man-LAM inhibited LPS-induced IL-12 promoter-driven lucifer-
ase gene expression. Given the important contribution of NF-B in
innate immunity, its direct role in production of cytokines as well as
induction of apoptosis as a response of the macrophage encountering a
pathogen, microbes have evolved strategies to limit NF-B activation.
The mechanisms through which activation of NF-B is counteracted
has been best studied in viruses (58, 59). We evaluated the possibility of
Man-LAM attenuating NF-B activation. Pretreatment with Man-
LAM was indeed found to attenuate LPS-induced 4 B-driven lucif-
erase gene activation. At the same time, we could demonstrate attenu-
ation of nuclear translocation of p50 and c-Rel, the principal players in
LPS-induced NF-B activation. One of the mechanisms of attenuation
of NF-B activation involves negative regulation of this pathway
through the induction of negative regulators such as IRAK-M. In the
present study we observed that Man-LAM could elicit Irak-M expres-
sion in RAW264.7 cells, suggesting that the inhibitory effect of Man-
LAM was likely being mediated through this negative regulator of TLR
signaling. RNA interference is a mechanism for sequence-specific post-
transcriptional inhibition of gene expression via double-stranded RNA
molecules. Small interfering RNAs are 21–23-nucleotide long RNA
duplex molecules that when transfected into mammalian cells cause
inhibition of a variety of signaling molecules (30, 46). This technique
was used to specifically knock down the expression of Irak-M. The
reinstatement of LPS-induced IL-12 production in cells pre-exposed to
Man-LAM suggested that induction of Irak-Mwas crucial to the inhib-
itory effect of Man-LAM.
Repression of IL-12 productionmay enhance the survival ofM. tuber-
culosis against the innate immune response or the developing adaptive
immune response. Understanding the mechanism of attenuation of
TLR agonist-stimulated IL-12 expression by Man-LAM provides new
insight into tuberculosis pathogenesis. Man-LAM triggered induction
of IRAK-M could likely contribute to the suppression of a second wave
of TLR signaling by giving rise to a tolerant phenotype thereby prevent-
ing excessive production of NF-B-dependent proinflammatory cyto-
kines. Although it has been established for some time thatM. tubercu-
losis uses various effectors such as Man-LAM to attenuate IL-12
induction, this is the first mechanistic insight into how this is achieved.
Detailed understanding of these processes could help in developing
novel therapeutic strategies against tuberculosis.
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